NCT Number: NCT00161772
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine in healthy children aged 1 to 6 years.
Looking for future studies?
Notify MeKey information
Conditions
Age range
1 year–5 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Grieskirchner Strasse 17, Wels, Austria
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Male and female children will be eligible for participation in this study if:
- they are 1 year (from the 1st birthday) to 6 years (to the last day before the 6th birthday) old;
- they are clinically healthy;
- their legal representative understands the nature of the study, agrees to its provisions and gives written informed consent;
- their legal representative agrees to keep a Volunteer Diary.
Exclusion criteria
Children will be excluded from participation in this study if they:
- have a history of any previous TBE vaccination;
- have a history of TBE infection or show evidence of a latent TBE infection (as demonstrated by screening ELISA > 126 VIEU/ml and / or neutralization test > 1:10);
- have a history of allergic reactions, in particular to one of the components of the vaccine;
- have received antipyretics within 4 hours prior to the first TBE vaccination;
- suffer from a disease that cannot be effectively treated or stabilized;
- suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment that can be expected to influence immunological functions;
- suffer from chronic, degenerative and / or inflammatory disease of the central nervous system;
- are known to be HIV positive (a special HIV test is not required for the purpose of the study);
- suffer from a febrile illness at study entry;
- have a history of vaccination against yellow fever and / or Japanese B-encephalitis;
- are participating simultaneously in another clinical trial.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Pfizer
Industry
Registry information
Official study title
Double-blind, Randomized, Multicenter Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
Important dates
- Study start
- 2002
- Study completion
- 2002
- First posted
- Sep 13, 2005
- Registry last updated
- May 21, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tick-borne Encephalitis Virus Research in Limousin
NCT05941546
Arbovirus Infections, Brain Diseases
Limoges, France
View Trial DetailsStudy to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
NCT04648241
Arbovirus Infections, Brain Diseases
Fukuoka, Japan
View Trial DetailsNew Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
NCT02318069
Arbovirus Infections, Brain Diseases
Helsinki, Finland
View Trial DetailsCervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac
NCT01710189
Arbovirus Infections, Brain Diseases
Guildford, Surrey, United Kingdom
View Trial Details